Gallen International Expert Consensus Conference classification): luminal (HR+) subtype classified according to the phosphoinositide 3-kinase (PI3K) status: wild-type or mutated; HER2+ disease; triple-negative subtype (HR−/HER2−) currently subclassified according to the programmed death ligand 1 (PDL-1) status, either ≥1 (positive on immune cells) or 0 (negative) with the creation of quadruple negative entity when PDL-1 is absent; and breast cancer gene (BRCA) mutated cancers5–7. The gene discussed is CD274; the disease is cancer.